TTOO (T2 Biosystems) Research & Development : $12.92 Mil (TTM As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is T2 Biosystems Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. T2 Biosystems's Research & Development for the three months ended in Sep. 2024 was $2.67 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 was $12.92 Mil.

T2 Biosystems Research & Development Historical Data

The historical data trend for T2 Biosystems's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

T2 Biosystems Research & Development Chart

T2 Biosystems Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

Get a 7-Day Free Trial

16.33

16.11

21.80

25.72

14.15

T2 Biosystems Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Research & Development	Get a 7-Day Free Trial															2.66	3.17	3.72	3.36	2.67

T2 Biosystems Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $12.92 Mil.

T2 Biosystems (NAS:TTOO) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

T2 Biosystems Research & Development Related Terms

Thank you for viewing the detailed overview of T2 Biosystems's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

T2 Biosystems Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » T2 Biosystems Inc (NAS:TTOO) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

0A57:UK 3T2:Germany

Address

101 Hartwell Avenue, Lexington, MA, USA, 02421

Website

https://www.t2biosystems.com

T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology.

Executives

David B Elsbree	director	C/O ACME PACKET, INC., 100 CROSBY DRIVE, BEDFORD MA 01730
Cr Group L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Unlev Aiv I L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Lev Aiv I L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund B (cayman) L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund (a) L.p.	10 percent owner	C/O CAPITAL ROYALTY L.P., 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Michael Terrence Gibbs	officer: General Counsel	12 STONEY BROOK RD., HOPKINTON MA 01748
John M Sprague	officer: Chief Financial Officer	101 HARTWELL AVE., LEXINGTON MA 02421
Sperzel John J Iii	director, officer: See Remarks	61 CRESTVIEW LANE, BRUNSWICK ME 04011
Brett A. Giffin	officer: Chief Commercial Officer	101 HARTWELL AVE., LEXINGTON MA 02421
Alec Barclay	officer: SVP, Operations	101 HARTWELL AVE., LEXINGTON MA 02421
Aparna Ahuja	officer: Chief Medical Officer	101 HARTWELL AVENUE, LEXINGTON MA 02421
Laura Lee Adams	director	101 HARTWELL AVE., LEXINGTON MA 02421
Anthony Pare	officer: Chief Commercial Officer	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184